COVID-19 Vaccine Pediatric Study

Why are we offering this option?

Pfizer and BioNTech are conducting a study to further evaluate the safety, tolerability, and immunogenicity of the Pfizer-BioNTech COVID-19 vaccine in children 6 months to 11 years of age on a two-dose schedule (approximately 21 days apart). The study vaccine is the same vaccine, BNT162b2, that has received authorization for emergency use (EUA) by the U.S. FDA for individuals 16 and older. Younger children, who make up a significant portion of the total global population, will play a critical role in our continued fight against COVID-19. The Phase 1/2/3 study will enroll approximately 4,500 children aged 6 months to 11 years in the United States and Europe.

What will happen in the study?

Over the course of the study, your child’s health will be evaluated by our research nurse and physician.

All study-related care and evaluations will be at no cost to you or your insurance.

You and your child will need to track any side effects they may have. To make it easier, you will be given an electronic diary (e-diary). If you prefer, you can also download a secure app on your smartphone.

You will be reimbursed for expenses (such as parking, meals, travel) and time related to completing the e-diary.

All participants will have the opportunity to receive the COVID-19 study vaccine during their time in the trial.

Who Qualifies?

- Children who are 6 months old to 11 years old

Where will these visits be located?

PriMED Clinical Research
948 Patterson Road
Dayton, Ohio 45419

How can I learn more information or sign up?

Spots are limited! Contact our research team at 937-534-4238 if you would like more information or click the Sign-up now link below and complete the research inquiry form.